DUBLIN (BUSINESS WIRE) Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial in Japan evaluating TEPEZZA for the treatment of adults with chronic Thyroid Eye Disease (TED) and low clinical activity score (CAS), which is a measure of disease act.
Nationwide campaign spotlights mental health impact of living with TED For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics plc (Nasdaq: HZNP) is partnering
Horizon Therapeutics plc: Gail Devers, Three-Time Olympic Gold Medalist, Partners with the Graves Community to FOCUS on Thyroid Eye Disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.